AU2002322066A1 - N-terminally truncated galectin-3 and antibodies for treating cancer - Google Patents

N-terminally truncated galectin-3 and antibodies for treating cancer

Info

Publication number
AU2002322066A1
AU2002322066A1 AU2002322066A AU2002322066A AU2002322066A1 AU 2002322066 A1 AU2002322066 A1 AU 2002322066A1 AU 2002322066 A AU2002322066 A AU 2002322066A AU 2002322066 A AU2002322066 A AU 2002322066A AU 2002322066 A1 AU2002322066 A1 AU 2002322066A1
Authority
AU
Australia
Prior art keywords
antibodies
treating cancer
terminally truncated
truncated galectin
galectin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002322066A
Other languages
English (en)
Inventor
Gary A. Jarvis
Constance M. John
Hakon Leffler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MANDALMED Inc
Original Assignee
MANDALMED Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MANDALMED Inc filed Critical MANDALMED Inc
Publication of AU2002322066A1 publication Critical patent/AU2002322066A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2002322066A 2001-06-08 2002-06-10 N-terminally truncated galectin-3 and antibodies for treating cancer Abandoned AU2002322066A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29697001P 2001-06-08 2001-06-08
US60/296,970 2001-06-08
PCT/US2002/018478 WO2002100343A2 (fr) 2001-06-08 2002-06-10 Galectine-3, tronquee au niveau de son extremite n-terminale, a liberation prolongee et anticorps aux ligands glucidiques de la galectine-3 a utiliser dans le traitement du cancer

Publications (1)

Publication Number Publication Date
AU2002322066A1 true AU2002322066A1 (en) 2002-12-23

Family

ID=23144316

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002322066A Abandoned AU2002322066A1 (en) 2001-06-08 2002-06-10 N-terminally truncated galectin-3 and antibodies for treating cancer

Country Status (4)

Country Link
EP (1) EP1534317A4 (fr)
AU (1) AU2002322066A1 (fr)
CA (1) CA2488850A1 (fr)
WO (1) WO2002100343A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7432331B2 (en) 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
EP1617849B1 (fr) 2003-04-07 2008-06-18 Prospect Therapeutics, Inc. Composition et utilisation d'antagonistes de la galectine
CN104198712A (zh) * 2008-10-29 2014-12-10 Bg医药股份有限公司 半乳凝素-3免疫测定法
CN102488619B (zh) 2011-12-05 2014-08-06 上海交通大学 连续生产艾塞那肽微球的装置及控制微球释放速度的方法
US9907814B2 (en) 2012-12-20 2018-03-06 Henry Ford Health System Method for treating diastolic heart failure by inhibiting galectin-3
WO2015085207A1 (fr) * 2013-12-05 2015-06-11 Texas Tech University System Galectine-3 pour le traitement du cancer des ovaires
JP2017507128A (ja) * 2014-02-03 2017-03-16 テキサス テック ユニヴァーシティー システムTexas Tech University System ガレクチン−3阻害剤(gal−3m)は、プロテアソーム阻害剤と組み合わせて使用した場合、相加的な抗骨髄腫及び抗固形腫瘍効果、破骨細胞形成の減少及び器官保護と関係する
KR20170054429A (ko) 2014-09-03 2017-05-17 제네세규스 인코포레이티드 치료용 나노입자 및 관련 조성물, 방법, 및 시스템

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986006407A1 (fr) * 1985-04-23 1986-11-06 Medical Biology Institute IDENTIFICATION D'UNE PROTEINE DE LIAISON IgE PAR CLONAGE MOLECULAIRE
US20020019009A1 (en) * 1999-12-09 2002-02-14 Roggen Erwin Ludo High throughput screening (HTS) assays
WO2001068123A2 (fr) * 2000-03-13 2001-09-20 La Jolla Institute For Allergy And Immunology Activite chimiotactique de la galectine-3 a l'egard des monocytes

Also Published As

Publication number Publication date
EP1534317A4 (fr) 2005-10-12
CA2488850A1 (fr) 2002-12-19
WO2002100343A3 (fr) 2005-03-17
EP1534317A2 (fr) 2005-06-01
WO2002100343A2 (fr) 2002-12-19

Similar Documents

Publication Publication Date Title
AUPR395801A0 (en) Antibodies against cancer
AU2002338015A1 (en) Human CDR-grafted antibodies and antibody fragments thereof
IL200404A (en) Couplings of 191p4d12 (b) protein-binding antibodies and their use in the treatment of cancer
AU2002305478A1 (en) Conjugates of reduced antibodies and biomolecules
AU2001290860A1 (en) Spas-1 cancer antigen
AU2002364708A1 (en) Novel compositions and methods for cancer
AU2002349543A1 (en) Tumor antigens
AU2002351374A1 (en) Antibodies to treat cancer
AU2002322066A1 (en) N-terminally truncated galectin-3 and antibodies for treating cancer
AU2002315066A1 (en) Methods for making antibody fragments and compositions resulting therefrom
AU2002308642A1 (en) Methods for treating cancer
EP1469769A4 (fr) Nouvelles compositions et methodes contre le cancer
AU2002337943A1 (en) Novel compositions and methods for cancer
AU2002335667A1 (en) Modified reoviral therapy
EP1469870A4 (fr) Nouvelles compositions et methodes pour le traitement du cancer
AU2002337713A1 (en) Pharmaceutical compositions and methods for treating cancer
AU2001257325A1 (en) Cancer treatment
AU2002305138A1 (en) Methods and materials for cancer treatment
AU2002360815A1 (en) Human breast cancer biomarkers
AU5632500A (en) Cancer associated antigens and uses therefor
AU2002366364A1 (en) E2f and cancer therapy
AU2002351382A1 (en) Combination cancer therapy
AU2002360454A1 (en) Methods and compositions for treating cancer
AU2002363807A1 (en) Breast cancer associated polypeptide
AU2000243657A1 (en) Method of binding integrin for treatment of cancer

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase